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Abstract
Context and aims: Carboxylesterase 1 (CES1) appears to play an important role in the control of the metabolism of
triglycerides and cholesterol in adipocytes and other cell types including hepatocytes. Therefore, it is relevant to gain
insights into the genetic versus non-genetic mechanisms involved in the control of CES1 mRNA expression. Here, we
investigated CES1 mRNA expression level in adipose tissue and its association with measures of adiposity and metabolic
function in a population of elderly twins. Furthermore, the heritability of CES1 mRNA expression level in adipose tissue and
the effect of CES1 gene duplication were assessed.
Methodology: A total of 295 monozygotic and dizygotic twin subjects (62–83 years) with (n= 48) or without (n= 247) type 2
diabetes mellitus were enrolled in the study. They were subjected to a standard oral glucose tolerance test and excision of
abdominal subcutaneous fat biopsies during the fasting state. Levels of CES1 mRNA and copy number of the gene were
assessed by quantitative PCR.
Results: CES1 mRNA expression level in adipose tissue was positively associated with body-mass index (P,0.001),
homeostasis model assessment-insulin resistance (P= 0.003) and level of fasting glucose (P= 0.002), insulin (P= 0.006), and
triglycerides (P= 0.003). The heritability for the expression of CES1 mRNA in adipose tissue was high. CES1 gene duplication
was positively associated with insulin sensitivity (P= 0.05) as well as glucose tolerance (P= 0.03) and negatively associated
with homeostasis model assessment-insulin resistance (P= 0.02). Duplication of CES1 was not linked to mRNA level of this
gene (P= 0.63).
Conclusion: CES1 mRNA in adipose tissue appears to be under strong genetic control and was associated with measures of
metabolic function raising the possibility of a potential role of this enzyme in the development of type 2 diabetes mellitus.
Further studies are needed to understand the potential effect of CES1 gene duplication on adipocyte and whole-body
metabolic functions.
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Introduction
Adipose tissue is the major site for storage of cholesterol and
triglycerides in the body [1,2] The hydrolysis and esterification of
lipids in this tissue are closely regulated to maintain a tight balance
between lipid release, storage, and trafficking [3]. Disturbance of
this balance may lead to insulin resistance, increased plasma levels
of triglycerides, and obesity, i.e. components of the metabolic
syndrome [3].
Several enzymes are implicated in the lipid metabolism in
human adipose tissue [4]. This includes carboxylesterase 1 (CES1)
that seems to play an important role in the hydrolysis of cholesteryl
esters and triglycerides [5]. This enzyme uses a hydrolysis
mechanism with release of the alcohol substituent from the
substrate and formation of a fatty acyl-enzyme intermediate as the
first step followed by a second step consisting of reaction of the
intermediate with water and release of the acyl group-containing
molecule [6]. Apparently, CES1 also possesses cholesterol trans-
ferase activity that enables formation of cholesteryl esters in the
abundance of free cholesterol [7]. Hence, the enzyme appears to
be involved in the de-esterification as well as transesterification of
lipids.
A role of carboxylesterases in the lipid metabolism in humans is
supported by observations from animal models [8–10]. One such
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study showed that the hydrolysis of triglycerides in adipose tissue
was severely decreased in mice with global inactivation of Ces3,
recently annotated as Ces1d1, which is the murine ortholog of
human CES1 [8]. Moreover, liver specific inactivation of Ces1d1
in mice has been shown to be associated with significantly
decreased levels of very low density lipoprotein-triglycerides and -
cholesterol in plasma and moderately increased liver triglyceride
levels suggesting an important role of hepatic Ces1d1 in the lipid
metabolism [9].
Because CES1 has a potentially significant role in the lipid
homeostasis, and its activity has been suggested to be primarily
regulated on the transcriptional level [11], the amount of CES1
mRNA in adipose tissue may serve as an intermediate phenotype
providing important information about the mechanisms leading to
type 2 diabetes mellitus (T2DM). So far, the expression of CES1
mRNA in T2DM has not been examined. However, it has been
suggested that the expression of CES1 mRNA in human adipose
tissue is correlated with measures of adiposity and metabolic
function including waist circumference, homeostasis model assess-
ment-insulin resistance (HOMA-IR), triglyceride level, and plasma
insulin level [12–14]. In contrast, findings of a relationship
between CES1 mRNA level and other measures of metabolic
function such as body-mass index (BMI) and total cholesterol level
are inconsistent, possibly reflecting limited statistical power [13,14]
and inclusion of study participants with malignant diseases [14].
Since CES1 may play an important role in the mechanisms
leading to dysregulation of lipid and glucose metabolism and
eventually to T2DM [13,14], the heritability of the expression
level of CES1 mRNA in adipose tissue is of scientific interest. Yet,
this heritability has not been determined. Therefore, the relative
contribution of genetic and non-genetic variation to the expression
of CES1 mRNA in subcutaneous adipose tissue remains unknown.
A variety of genetic variations may influence CES1 mRNA
expression. One such variation is duplication of the gene [15] that
may result in increased production of CES1 mRNA and thus
increased CES1 activity albeit the ‘‘daughter’’ copy of the gene has
been reported to be transcribed at a lower level than the ‘‘mother’’
copy [16]. Since pseudogenes can affect the mRNA levels of their
protein-coding counterparts [17], another inherited factor that
could potentially modulate the level of mRNA of CES1 is
carboxylesterase 1 pseudogene 1 (CES1P1), located in the vicinity
of CES1 [18].
In the present study we examined a unique study population of
phenotypically well-characterized elderly monozygotic and di-
zygotic twin subjects (n= 295 individuals) with the aim of
providing new information about basal mechanisms underlying
T2DM by: 1) assessment of the relationship of CES1 mRNA
expression level in subcutaneous adipose tissue with age, gender,
measures of glucose and lipid metabolism, and CES1P1 mRNA
expression level; 2) determination of the heritability of CES1
mRNA expression in adipose tissue; 3) assessment of the relation-
ship of CES1 copy number with CES1 mRNA expression in
adipose tissue and measures of metabolic function in healthy and
T2DM subjects.
Materials and Methods
A total of 295 monozygotic (MZ) (n= 125; 48 complete pairs
and 29 single twins) and same-sex dizygotic (DZ) (n= 170; 55
complete pairs and 60 single twins) elderly Danish twin subjects
(62–83 years) were recruited as previously described [19,20].
Glucose tolerance status was determined employing a standard 75-
g oral glucose tolerance test (OGTT). The glucose tolerance status
was defined according to the WHO 1999 criteria [21] and ranged
from normal glucose tolerance (NGT, n= 169) over impaired
glucose tolerance (IGT, n= 78) to overt T2DM (n= 48). Twenty-
two subjects had known T2DM and were treated with diet or
glucose-lowering medication. An informed consent form was
signed by all subjects prior to their inclusion in the study. The
signed forms were kept by the principal investigator for
documentation purposes. The study with its consent procedure
was approved by the Committees on Biomedical Research Ethics
for the Capitol Region in Denmark and conducted in adherence
with the guidelines of the Helsinki Declaration.
Clinical Examination
Weight and height as well as waist and hip circumference were
measured, and BMI was calculated. Fasting blood samples were
analyzed for serum triglyceride and total cholesterol levels using
commercial kits from Boerhinger Mannheim (Mannheim, Ger-
many). Insulin resistance was assessed using HOMA-IR: (fasting
plasma insulin*fasting plasma glucose/22.5)*0.144 [22]. The
composite whole-body insulin sensitivity index (ISI)composite was
determined as follows: 10,000/sqrt([fasting glucose*fasting insu-
lin]*[mean glucoseOGTT*mean insulinOGTT]) [23].
Tissue biopsies. Subcutaneous adipose tissue biopsies were taken
from the abdomen in a subgroup of the study population (n= 226).
This was done under local anesthesia (lidocaine) using a Bergstro¨m
needle with suction applied. Specimens were quickly blotted onto
filter paper and frozen in liquid nitrogen.
Gene Expression
Total RNA was extracted using TRI reagent (Sigma-Aldrich,
St. Louis, MO) as described previously [24]. cDNA was
synthesized using QuantiTect Reverse Transcription Kit accord-
ing to the manufacturer’s recommendations (Qiagen, Valencia,
CA). We used the standard curve method for quantification of
mRNA by TaqManH-based PCR on an ABI Prism 7900 HT
system from Applied Biosystems, now Life Technologies Corpo-
ration (Carlsbad, CA). Using reagents also purchased from this
company, we determined the mRNA levels of CES1 in 206
individuals (assay identification Hs00275607_m1), while that of
CES1P1 only were determined in 159 individuals due to technical
issues (assay identification Hs00750233_s1). The mRNA levels
were normalized to that of PPIA, cyclophilin A, (part number
4326316E from Life Technologies Corporation) and expressed in
arbitrary units. Average Ct values were ,25 for CES1 and PPIA
and ,33 for CES1P1. The lower expression of CES1P1 and thus
larger variation between the duplicates allowed for fewer
duplicates to pass the criteria of a CV% ,1%.
Copy Number Determination of CES1
DNA was purified from leukocytes employing Autopure LSH
according to the manufacturer’s recommendations (Qiagen
GmbH, Hilden, Germany). The copy number determination
was performed using real-time PCR followed by comparison of the
amounts of gene-specific amplicon to that of a reference gene. For
this purpose commercially available fluorescent-labeled reagents
were acquired and applied according to the guidelines of the
manufacturer (Life Technologies Corporation). These reagents
targeted a region in exon 11 of CES1 (assay identification
Hs00139541_cn). The gene encoding the ribonuclease P RNA
component served as reference gene. Calculation of the gene copy
number was accomplished using CopyCaller v 1.0, a program
developed by the manufacturer of the assay reagents. In the event
of disagreement between duplicate samples, the analysis was
repeated. The observed genotype proportions were compared with
Carboxylesterase 1 and Metabolic Dysfunction
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those expected under Hardy-Weinberg equilibrium using chi-
squared test.
Statistical Methods
All statistical tests were performed using SAS (version 9.2, SAS
Institute, Cary, NC). Data were presented as mean6SD. P,0.05
was considered significant. Spearman’s rho was used to evaluate
the correlation between continuous variables. Multiple regression
analyses allowed for assessment of the effect of CES1 copy number
and CES1 mRNA level, while adjusting for twin and zygosity status
as well as for additional contributing variables, including age, sex,
and BMI [25]. All response variables were log-transformed to
avoid skewness of the residuals. This resulted in effects that
expressed percentage-wise and not absolute changes in the
response variable. Since CES1 mRNA level was expressed in
arbitrary units, the association of this variable with others was
calculated per doubling from its average. Doubling of the CES1
mRNA level was within 2 SD, which was considered to be
biologically plausible. The heritability coefficient, often abbrevi-
ated as h2, expresses the proportion of the total variation of a trait
attributable to genetic variation. In a twin population the
heritability coefficient can be calculated as the degree to which
MZ twins are more similar than DZ twins [26]. It was determined
as twice the difference of the intra-class correlation coefficients of
MZ and DZ twins (h2 = 2[rMZ2rDZ]). A heritability coefficient
approaching 0 indicates very limited genetic influence, whereas
a heritability coefficient close to 1 indicates that the trait is under
strong genetic control.
Results
Clinical Characteristics
The clinical characteristics of this population have been
described in detail previously [20].
CES1 and CES1P1 mRNA expression. CES1 mRNA expression
level in adipose tissue was significantly affected by age, gender, and
BMI (P,0.001 for all variables, Table 1). One year of aging was
associated with a decrease in the CES1 mRNA level of 4%, and the
expression level in males was 35% lower than in females. Adiposity
was associated with a 10% increase in CES1 mRNA level per BMI
unit (Table 1 and Figure 1A). Moreover, we found CES1 mRNA
level in adipose tissue to be positively associated with HOMA-IR
(Table 2 and Figure 1B), where a doubling of this level was
associated with a 15% increase in HOMA-IR (P= 0.003). CES1
mRNA level was also positively associated with other measures of
metabolic function (Table 2), including cholesterol (P= 0.04), and
fasting plasma levels of insulin (P= 0.006), glucose (P= 0.002) and
triglycerides (P= 0.003, see also Figure 1C). Conversely, CES1
mRNA level was negatively associated with ISIcomposite (P= 0.005).
Finally, there was a positive correlation between the levels of
mRNA of CES1 and CES1P1 (Figure 1D). Although CES1 mRNA
level was not significantly associated with 120-min OGTT glucose
level (Table 2), we found a borderline significant association
(P= 0.057) between the levels of OGTT glucose and CES1 mRNA
after adjustment for age, sex and BMI (Figure 2). Individuals with
IGT and T2DM were combined into one group with impaired
glucose regulation. After adjustment for age, sex and BMI the level
of CES1 mRNA was 27% higher in the combined group compared
with the NGT group (Figure 2).
Heritability of CES1 and CES1P1 mRNA Expression
The heritability coefficients for the mRNA expression of CES1
and CES1P1 amounted to ,1 and 0.84, respectively. This
suggested that genetic effects exhibited a quantitatively pre-
dominant influence on the variation of the mRNA expression of
these two genes in adipose tissue (Table 3).
CES1 copy number variation. Since the CES1 mRNA expression
level in adipose tissue was found to be highly heritable and
significantly associated with numerous measures of metabolic
function, we evaluated the effect of CES1 duplication, a genetic
variation that previously has been suggested to affect the transcript
abundance of this gene [16]. Among the subjects in the study
population, 6 carried the duplicated allele on both chromosomes,
60 were heterozygotes for this allele, and 138 did not carry the
duplicated allele. Based on this observation, the frequency of the
duplicated CES1 allele was estimated at 0.18. The genotype
proportions conformed to those expected under the condition of
Hardy-Weinberg equilibrium (P= 0.86). Due to the small number
of subjects having 4 gene copies of CES1, we amalgamated the
groups with 3 and 4 copies of CES1 (Table 4). Using this approach
we found decreases of 5% and 14% in the fasting level of glucose
(P= 0.06) and insulin (P= 0.04), respectively, in the group of
subjects with 3 or 4 CES1 gene copies, while there was a 9%
increase in ISIcomposite (P= 0.05) in this group compared with
individuals harboring 2 copies of the gene (Table 4). Moreover, we
found a 19% decrease in of HOMA-IR (P= 0.02) and an 11%
decrease in OGTT (P= 0.03) in the group of subjects with 3 or 4
CES1 gene copies. There was no significant association between
the gene copy number and CES1 mRNA expression (P= 0.63).
Furthermore, CES1 copy number was not associated with
measures of adiposity or plasma lipid parameters, including
plasma triglyceride and total cholesterol levels. Statistical analysis
without amalgamation of the groups with 3 and 4 CES1 copies
produced results that were comparable to those obtained with
amalgamation. However, a larger effect of CES1 copy number was
observed on HOMA-IR (P= 0.002) and level of fasting insulin
(P= 0.002) without the amalgamation.
Discussion
In the present study the mRNA expression level of CES1 in
subcutaneous adipose tissue samples derived from monozygotic
and dizygotic twins was examined. We report several important
findings about the regulation and possible role of CES1 in the lipid
and glucose homeostasis. First, we found significant relationships
between CES1 mRNA level and age, gender, measures of
adiposity, metabolic regulation and CES1P1 mRNA level. Second,
a high heritability for the level of mRNA expression of CES1 was
detected. Third, CES1 gene copy number was found to be
associated with measures of glucose metabolism. Collectively,
these findings suggest that CES1 is involved in the pathogenesis of
T2DM.
Our study is the first to report that CES1 mRNA level in
subcutaneous adipose tissue is negatively correlated with age in
a population of elderly subjects, and that CES1 is transcribed at
significantly higher levels in women than men. Although a previous
small-sized study also found CES1 mRNA expression level in
visceral adipose tissue to be inversely associated with age, the
association for subcutaneous adipose tissue in this study did not
reach statistical significance. However, since the age span in the
present study was only 21 years with the youngest subject being 62
years old, it cannot be excluded that age affects CES1 mRNA level
in adipose tissue differently in younger individuals. The strong
correlations of CES1 mRNA level with BMI, total cholesterol, and
fasting plasma glucose and insulin levels observed in the present
study are remarkable and may clarify disagreeing findings
observed in previous studies [13,14]. For example, one study
reported lack of association of CES1 mRNA level with BMI [13],
Carboxylesterase 1 and Metabolic Dysfunction
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while another study found a strong positive correlation between
these two variables [14]. Based upon a large sample our findings
support the latter of these two studies. The finding that individuals
with dysregulated glucose metabolism, including those with
T2DM, displayed higher levels of CES1 mRNA underscores the
association of CES1 with glucose metabolism. Our finding of
a positive correlation between the expression level of mRNA of
CES1P1 and CES1 is interesting and since pseudogenes can affect
the levels of mRNA of their protein-coding counterparts
[17,27,28], it suggests a novel mechanism for regulation of the
Figure 1. Correlation between CES1 mRNA expression level and selected variables. Correlation of CES1 mRNA level with body-mass index
(BMI) (A, n= 204 twin subjects), homeostasis model assessment-insulin resistance (HOMA-IR) (B, n= 203 twin subjects), fasting plasma triglyceride
levels (C, n=205 twin subjects), and CES1P1 mRNA level (D, n=147 twin subjects), respectively, are shown. Due to technical reasons the level of
CES1P1 mRNA could not be determined in a relatively large subpopulation of the twin subjects (for explanation, see ’’Materials and Methods‘‘). CES1:
Carboxylesterase 1 gene; CES1P1: carboxylesterase 1 pseudogene 1; TG: triglyceride. Spearman’s rho correlation coefficients and the corresponding P-
values have been included.
doi:10.1371/journal.pone.0056861.g001
Figure 2. CES1 mRNA expression level in adipose tissue in individuals with normal glucose tolerance (NGT), impaired glucose
tolerance (IGT), type 2 diabetes mellitus (T2DM), and impaired glucose regulation (IGR= IGT+T2DM). CES1: carboxylesterase 1 gene.
*P,0.05 compared to NGT after adjustment for age, gender, and body-mass index.
doi:10.1371/journal.pone.0056861.g002
Carboxylesterase 1 and Metabolic Dysfunction
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CES1 mRNA expression in adipose tissue. Previous observations
have suggested that the transcripts of a pseudogene and its
functional counterpart can compete for the same transacting
factors involved in mRNA degradation [27]. Therefore, high levels
of transcripts generated from a pseudogene may efficiently protect
the transcripts of a functional homolog from degradation, thus
increasing its translation. Whether such mechanism is involved in
the regulation of CES1 activity is not known. Of importance,
a pseudogene has previously been associated with insulin re-
sistance and T2D by another posttransciptional regulation
mechanism that involved destabilization of the transcripts
generated from a functional homolog [29].
There are several plausible explanations for the observed
associations between the level of CES1 mRNA in subcutaneous
adipose tissue and measures of glucose metabolism. Notably,
increased CES1-mediated lipolysis in adipose tissue could cause
disturbances of the glucose metabolism by elevation of the plasma
levels of non-esterified fatty acids that can induce muscle and
hepatic insulin resistance [30,31] Also, cholesterol imbalance in
adipocytes seems capable of inducing insulin resistance [2] and
since CES1 is believed to have an important role in regulating the
ratio of esterified and non-esterified cholesterol [32], such
regulating role of CES1 could be reflected in the appearance of
an association between levels of CES1 mRNA and cholesterol.
Alternatively, imbalance in the metabolism of cholesterol or other
lipids due to intake of a diet rich in animal fat may lead to an
altered blood lipid profile [33,34] and increments in body fat
deposits [35] that might affect the expression of CES1 mRNA.
In the present study, the heritability of CES1 mRNA expression
in subcutaneous adipose tissue was high, exceeding the average
heritability of 0.234 for the mRNA expression across genes in
subcutaneous adipose tissue previously obtained by analysis of
a family cohort [36]. Heritability coefficients have several
limitations. For example, they can be inflated by shared pre- as
well as post-natal environments [37]. However, even with this
limitation the present study suggests the existence of a strong
heritable component in the expression of CES1 mRNA in adipose
tissue. A strong heritable component in the transcription is
characteristic of genes whose transcriptional levels are determined
by local regulatory variation [38,39]. Hence, the individual
differences in the expression level of CES1 mRNA observed in
the present study may to large extent reflect variation within this
gene or in genes in its vicinity.
A genetic variation potentially conferring individual differences
in the expression of CES1 is duplication of the gene [15,16].
Previously, the frequency of the duplicated allele of CES1 was
determined at 0.20 among voluntary blood donors in Denmark
(Rasmussen et al., unpublished results). Although slightly lower,
the observed frequency of this allele in the present study, based
upon related as well as unrelated subjects, was in accordance with
this value. Apparently, the transcription in adipose tissue by
genotypes with 3 or 4 copies of CES1 was comparable with that of
genotypes composed of 2 copies of the gene. Probably, this reflects
that the ‘‘daughter’’ copy, often designated CES1A2, is transcribed
at a low level and therefore does not contribute substantially to the
total amounts of CES1 transcripts. This is in agreement with
findings obtained by analysis of human livers [15], while the
expression of CES1A2 has been found to be high in several cell
lines [16]. In addition to gene duplication, variation in the
promoter region of a gene can affect the amounts of transcripts
produced. There are several promoter variants in CES1 with
a presumed effect on the transcription of this gene [40,41].
However, these effects remain to be confirmed.
The copy number of the gene encoding CES1, including
‘‘mother’’ as well as ‘‘daughter’’ copies, was associated with several
measures of glucose metabolism. More specifically, presence of 2
copies of CES1 appeared to predispose to a negative phenotype
and influence the susceptibility to T2DM suggesting that the
present study identified a novel genetic factor affecting the risk of
developing this disorder. In this regard, the lack of association
between CES1 gene copy number variation and mRNA level in
adipose tissue is surprising, when this genetic variation is proposed
to have effects on glucose and lipid metabolisms. One explanation
for this apparent discrepancy may be that the duplicated version of
CES1 is in linkage disequilibrium with a gene variant that affects
glucose metabolism indirectly or directly without increasing the
Table 1. Effect of selected variables on CES1 mRNA
expression level in adipose tissue.
Explanatory variable Regression coefficient P-value
Age (effect of 1 year) 24% ,0.001
Gender (effect of the male gender) 235% ,0.001
BMI (effect of 1 BMI unit) +10% ,0.001
The statistical model is: ln(CES1 mRNA level) = age+gender+BMI. The regression
coefficient expresses the change in the response variable associated with an
increase of one unit in an explanatory variable. CES1: carboxylesterase 1 gene;
BMI: body-mass index.
doi:10.1371/journal.pone.0056861.t001
Table 2. Association between CES1 mRNA expression level in
adipose tissue and measures of glucose and lipid metabolism.
Response variable Regression coefficient P-value
HOMA-IR +15% 0.003
ISIcomposite 210% 0.005
120-min glucose, OGTT +3% 0.23
Fasting triglyceride level +10% 0.003
Fasting insulin level +12% 0.006
Fasting glucose level +3% 0.002
Total cholesterol level +3% 0.04
The statistical model is: ln(response variable) = age+sex+BMI+CES1 mRNA level.
The regression coefficient expresses the change in the response variable
associated with a doubling of CES1 mRNA level from its average. CES1:
carboxylesterase 1 gene; HOMA-IR: homeostasis model assessment-insulin
resistance; ISIcomposite: insulin sensitivity index (composite); OGTT: oral glucose
tolerance test.
doi:10.1371/journal.pone.0056861.t002
Table 3. Heritability of CES1 and CES1P1 mRNA expression
levels in adipose tissue.
Variable rMZ rDZ h
2
CES1 0.82 (n = 23 pairs) 0.26 (n=32 pairs) ,1
CES1P1 0.78 (n= 14 pairs) 0.36 (n=24 pairs) 0.84
The heritability was determined as: h2 = 2[rMZ2rDZ]. In this equation h
2 is the
heritability coefficient; rMZ and rDZ are intra-class correlations within
monozygotic (MZ) and dizygotic (DZ) twins, respectively. Due to missing
biopsies or technical issues we only determined CES1 and CES1P1 mRNA level in
a subgroup of the twin subjects. CES1: carboxylesterase 1 gene; CES1P1:
carboxylesterase 1 pseudogene 1.
doi:10.1371/journal.pone.0056861.t003
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expression of CES1 mRNA. An alternative possibility is that CES1
activity in adipose tissue is predominantly regulated by post-
transcriptional mechanisms including pseudogene-mediated tran-
script protection, a mechanism that appears to play a role in the
regulation of several other genes [17,27,28]. This is an interesting
possibility since the haplotype harboring the duplicated allele lacks
CES1P1, while this pseudogene is present on the haplotype with
the unduplicated allele [15]. Therefore, the latter of these two
haplotypes has a potential for generation of CES1P1 transcripts.
Pseudogenes may act through different mechanisms [17,27,28].
Notably, antisense transcripts generated from these genetic
elements have been implicated in the translational silencing of
their functional homologs [17,28]. It is possible that pseudogen-
mediated posttranscriptional regulation is involved in determining
CES1 activity and that this explains some of the findings from the
present study. Regulation of the activity of CES1 may, however,
be even more complex as it also seems to include regulatory
control on the protein level by endogenous small molecules, such
as cholesterol-like molecules [32]. Therefore, CES1 activity may
not be correlated with level of CES1 mRNA and copy number
status of CES1.
Various aspects of the role of CES1 in lipid metabolism remain
to be clarified including the importance of CES1-mediated
lipolysis in adipose tissue relative to that in the liver. A recent
study raised doubts about the importance of CES1 in the
hydrolysis of triglycerides in adipose tissue and suggested that
other lipases were more important in this respect [12], while
another study reported a major role of CES1 in the trafficking of
lipids and lipid metabolism in hepatocytes [42]. Whether CES1 is
more important to the triglyceride metabolism in the liver than
adipose tissue of humans is not yet known. However, using mice
with global knock-out of Ces1d1, the murine ortholog of the
human CES1, a recent study attributed most of the reduction in
plasma triglycerides resulting from this gene knock-out to the
absence of hepatic activity of Ces1d1 [9]. If CES1 has a role in the
metabolic regulation in the liver that is comparable to its murine
ortholog, this would explain our finding that CES1 gene copy
number was associated with insulin resistance in the fasting state
(HOMA-IR), which is thought to be primarily hepatically
determined [43].
The positive association between CES1 gene copy number and
ISIcomposite suggests that variations in this gene impacts on the
peripheral insulin sensitivity [23], possibly affecting glucose
metabolism or insulin sensitivity in skeletal muscle. Although it is
known that insulin sensitivity is under strong genetic control
[44,45], very few genetic variations affecting insulin sensitivity in
the liver or skeletal muscle have been identified so far. Our results,
suggest that copy number variation of CES1 could be involved in
mediating such effects. Finally, besides the association with
ISIcomposite, CES1 copy number was associated with glucose
tolerance, a positive association that might reflect an effect on beta
cell function and insulin secretion.
In conclusion, the present study links the expression level of
CES1 mRNA with risk factors for T2DM and suggests that copy
number variation of CES1 influences measures of glucose
metabolism, perhaps contributing to the genetic susceptibility to
T2DM. This knowledge may be valuable for future research
aimed at understanding the genetic architecture predisposing for
T2DM.
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